“If you get a drug that targets a human protein, it would be incredibly hard for the virus to mutate away from being reliant on it,” said Nevan Krogan, the director of QBI.
“This is looking across coronaviruses and finding the commonalities so we’re in a better position to attack SARS3 when it comes,” said Nevan Krogan, the director of QBI.